PDCD1 and hepatocellular carcinoma: The emergence of immunotherapy, particularly agents targeting the programmed cell death protein 1 (PD-1) and programmed cell death ligand-1 (PD-L1) pathway, has transformed HCC management, achieving remarkable clinical success [6].